Why Did Fulgent Genetics Inc. (FLGT) Soar 11.24%?

Fulgent Genetics Inc. (FLGT) shares surged 11.24% in pre-market trading on May 1, 2025, driven by a combination of positive analyst ratings and upcoming earnings reports.

Analysts have given FLGT buy signals from both short and long-term moving averages, indicating a positive outlook for the stock. This bullish sentiment is further supported by the company's upcoming earnings report, which is expected to show a loss of $0.19 per share but revenue of $71.26 million for the quarter.

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's stock performance has been closely watched by investors, with recent trading activity showing a slight decline to $17.45 per share.

Despite the recent volatility, the overall market sentiment towards FLGT remains positive, with analysts expecting the stock to perform well in the coming weeks. Investors are advised to keep an eye on the company's earnings report and any updates on its diagnostic and therapeutic development solutions.